Cramer's Mad Dash: Johnson & Johnson

Group 1 - The FDA has approved Capita for the treatment of major depressive disorder, marking a significant advancement in the field [1][2] - Johnson & Johnson (J&J) is recognized for its pioneering efforts in addressing mental health issues, including suicide prevention and major depressive disorder [2] - The approval of Capita is expected to have a substantive impact on the market and add to J&J's portfolio of mental health treatments [2] Group 2 - Everimmune, a biotech company focused on chronic inflammatory diseases, is celebrating its IPO at Nasdaq [3] - Billion to One, a molecular diagnostics company, is also marking its five-year anniversary, highlighting its success in the diagnostics sector [3]